Table 3.
Prevalence |
|||||||
---|---|---|---|---|---|---|---|
ANTR | Self-report | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Kappa | |
Cancer (all-sites) | 99 | 140 | 86.9 (80.2–93.5) | 98.5 (98.1–98.9) | 61.4 (53.4–69.5) | 99.6 (99.4–99.8) | 0.71 (0.64–0.78) |
Breast (F) | 34 | 33 | 85.3 68.9–95.1) | 99.8 (99.7–99.9) | 87.9 (71.8–96.6) | 99.8 (99.7–99.9) | 0.86 (0.78–0.95) |
Colorectal | 14 | 21 | 78.6 (49.2–95.3) | 99.7 (99.5–99.9) | 52.4 (29.8–74.3) | 99.9 (99.8–99.9) | 0.63 (0.44–0.81) |
Prostate (M) | 7 | 8 | 100 (54.1–100) | 99.9 (99.8–99.9) | 75.0 34.9–96.8) | 100 (99.9–100) | 0.86 (0.66–1.0) |
aFor the purposes of these comparisons, ANTR was treated as the reference. However, PPV and NPV, respectively, reflect sensitivity and specificity if self-report is substituted for the reference.